Scientific deep-dive

GLP-1s After a Kidney Transplant

A meta-analysis of 54,680 transplant recipients reports mortality nearly halved and kidney function improving. Four studies stand behind the mortality figure, and the size of the benefit is the reason to be careful with it.

By Nora Bissett · Pricing Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed
6 min read·1 citation

Metabolic complications after a kidney transplant drive how long the graft and the patient last. A 2026 meta-analysis pooled 17 studies covering 54,680 transplant recipients and reported results that look almost too good: mortality nearly halved, cardiovascular events nearly halved, kidney function improving rather than declining.[1] The size of those numbers is the reason to be careful with them.

What was reported

Pooled outcomes in kidney transplant recipients using GLP-1 drugs. The Studies column gives the number of studies behind each figure.
OutcomePooled resultStudies
All-cause mortalityHR 0.53 (95% CI 0.36–0.79)4
Major adverse cardiovascular eventsOR 0.55 (95% CI 0.47–0.66)3
eGFR at 6 months+1.99 mL/min/1.73m² (0.52–3.47)5
eGFR at 12 months+2.24 mL/min/1.73m² (0.02–4.46)6
HbA1c−0.54% (95% CI −0.89 to −0.19)13

Kidney function was stable at three months, improved at six and twelve, and was preserved at twenty-four.[1] For a transplanted kidney, not declining is itself the goal.

Why a 47% mortality reduction should make you cautious

Drugs rarely halve mortality. Confounding by indication routinely produces results that look like that, and this evidence is entirely observational.

Consider who receives a GLP-1 after a transplant. It is the recipient doing well enough that a nephrologist turns attention to long-term metabolic risk, not the one with an unstable graft, active infection, or poor functional status. Those patients would have lower mortality than the comparison group whatever they were prescribed. A hazard ratio of 0.53 is the kind of result that selection produces.

The mortality figure rests on four studies and the cardiovascular figure on three, so read the Studies column before the confidence interval.

The HbA1c and eGFR results are more believable because they are less impressive. A 0.54 point reduction in HbA1c, pooled from thirteen studies, is in line with what these drugs produce. An eGFR gain of about two units, from five and six studies, is small, consistent, and measures something that resists wishful reporting. Whether weight loss alone can flatter an eGFR is a fair question, and one trial tested it against directly measured filtration.

What makes this population different

  • Immunosuppression is narrow-therapeutic-index prescribing. Tacrolimus levels are monitored closely for good reason, and anything that changes absorption is a live concern, which is why this belongs with the transplant team rather than a telehealth intake. Our interactions article covers the general mechanism.
  • Post-transplant diabetes is common and partly caused by the immunosuppression itself, so metabolic treatment is not optional add-on care here.
  • The graft is the outcome. Weight is a means to it rather than the point, which changes how a benefit-risk conversation runs.
  • Dehydration matters more. Gastrointestinal effects that are unpleasant in the general population are a graft-function concern in someone with a single functioning kidney.
Nothing here is a reason to seek a GLP-1 from a telehealth seller after a transplant. This is prescribing that needs to sit alongside immunosuppression monitoring, and a platform that has never seen your tacrolimus levels cannot do it. If a seller’s intake does not ask about transplant history, that tells you something about the intake.

Where this leaves a patient

A patient here is in an unusually good position, with an unusually weak evidence base. The direction of every measured outcome is favorable, the mechanism is plausible, and the population has a great deal to gain. What is missing is a randomized trial. Until there is one, the drugs look useful here and the size of the reported benefit is probably not real.

That is a reasonable basis for a conversation with a transplant nephrologist, and not a basis for confidence about how much benefit to expect.

Frequently Asked Questions

They do, and a 2026 meta-analysis of 17 studies in 54,680 recipients found favorable results across mortality, cardiovascular events, HbA1c and kidney function. All of it is observational, so it belongs in a conversation with the transplant team rather than being treated as established.
Almost certainly not. The pooled hazard ratio was 0.53, but it rests on four studies and the evidence is observational. Nephrologists prescribe these drugs to recipients who are doing well enough to be thinking about long-term metabolic risk, and that selection alone can produce a result of this size.
This is the more trustworthy part. eGFR was stable at three months, improved by about 2 mL/min/1.73m² at six and twelve months, and was preserved at twenty-four. The changes are small and consistent, and for a transplanted kidney, not declining is the goal.
It is the right question to ask your transplant team. Immunosuppressants such as tacrolimus are monitored closely because the therapeutic window is narrow, and any drug that alters absorption warrants attention. In the 2026 meta-analysis, tacrolimus levels were unaffected at six months and modestly lower at one year, without harm to graft function. This is a reason for the prescribing to sit with the transplant service.
You should not want to. This prescribing needs to sit alongside immunosuppression monitoring, and a platform that has never seen your levels cannot do that. An intake that does not even ask about transplant history is telling you something about the intake.

References

  1. 1.Kanbay M, Abdel-Rahman SM, Guldan M, et al. Clinical outcomes of glucagon-like peptide-1 receptor agonist therapy in kidney transplant recipients: a systematic review and meta-analysis Clinical Kidney Journal. 2026. PMID: 42017027.

Jardiance or Farxiga With Ozempic or Mounjaro: Taking an SGLT2 and a GLP-1

SGLT2 inhibitors like Jardiance and Farxiga are routinely taken with Ozempic or Mounjaro, and no label forbids it. Sugar and weight effects add up in trials; heart and kidney gains rest on subgroups. The real overlap is dehydration and ketoacidosis.

12 min read

GLP-1 Drugs and Kidney Stones: What the Labels and Studies Show

No trial was designed to test whether Ozempic, Wegovy, Mounjaro or Zepbound cause kidney stones. Wegovy's label reports urinary stones in 1.2% vs 0.8% on placebo in a heart trial; the other labels are silent. What the cohorts, urine studies and fluid data show.

10 min read

How Many People to Treat to Help One

Trials report benefit as a percentage, which sounds impressive and tells you nothing about your own odds. FLOW published the number needed to treat instead: 22, 13 and 17 over three years.

7 min read

Where the Evidence Is Strongest

Most of what this register examines has something wrong with it. This does not: a synthesis of 13 trials rates the cardiovascular and kidney benefits in chronic kidney disease at high certainty.

7 min read

Tirzepatide vs Dulaglutide: A Real Head-to-Head

13,299 people randomized to one drug or the other, followed four years. Kidney events occurred in 6.0% on tirzepatide against 7.6% on dulaglutide, and nausea, vomiting and diarrhea were all more common on tirzepatide.

6 min read

Does Weight Loss Fake Kidney Numbers?

Estimated kidney function is calculated from creatinine, and creatinine comes from muscle, so weight loss could flatter the number. A trial checked the estimates against a directly measured filtration rate.

7 min read

Where to get GLP-1 online, safely: sellers our editors have checked

These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.

No insurance needed · vetted by our editors

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

8.6

Strut Health

Semaglutide at $99/month, well below the typical price

7.9

ShedRx

Oral orforglipron alongside the injectables

From $149/mo + membership

Get started →
Read full review →
8.1

Sesame Care

Oral orforglipron alongside the injectables

About this analysis

GLP Watchdog publishes independently. Each seller in our dataset is checked against that seller's own website, and the dataset is updated continuously. Read our full methodology →